TP53 and acute myeloid leukemia: The importance of detecting TP53 mutations in all AML age categories is justified by the fact that the presence of TP53 mutations contribute to a very high risk of treatment failure with standard chemotherapy approaches and thus TP53 status is an important consideration for designing novel therapeutic strategies for AML.